header image

Últimas notícias

Octapharma USA Focuses on Urgent Surgeries as FDA Approves octaplex® for Fast Track Development


Therapy May Stem Spontaneous Bleeding Episodes, Mortality Rates   The U.S. Food and Drug Administration (FDA) has approved Octapharma USA’s Investigational New Drug Application for octaplex® (Human Prothrombin Complex,...

Octapharma is Terminating the Plasma Therapeutics Association Global Membership


Octapharma has notified the Plasma Protein Therapeutics Association that it is terminating its Global Membership and Regional Membership in the organization.

Convincing Results From Study on octagam 10% in ITP Published in "Hematology"


Lachen, Switzerland, (24 Sept 2010) – Octapharma AG today announced the publication of the recently concluded octagam®10% study in the indication Immune Thrombocytopenic Purpura (ITP) in the scientific journal “Hematology”.

Urgent: Voluntary market withdrawal - September 24, 2010 octagam (Immune Globuline Intravenous (human) 5% Liquid Preparation)


Dear Healthcare Professional On August 20, 2010, in the interest of patient safety, Octapharma USA Inc. initiated a voluntary market withdrawal of selected lots of octagam® [Immune Globulin Intravenous (human)] 5% Liquid...

Update: Product Withdrawal/Product Recall - octagam (octagam 50mg/ml) and octagam 10% (octagam 100mg/ml)


In response to current measures taken related to the recent increase in the reporting frequency of thromboembolic events (TEEs) in connection with octagam® (human normal immunoglobulin for i.v. administration, 50 mg/ml),...

The Next-Generation VWF/FVIII Concentrate, Wilate®, Strives to Reflect the Normal Physiological Condition


World Haemophilia Experts Present Octapharma's Newest Product Specifically Developed for Patients with von Willebrand Disease